Bringing Alpha Therapies into Clinical Practice

This online course offers a comprehensive introduction to alpha therapy in nuclear medicine, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available, describing all important steps required for production and radiopharmaceutical development. The advantages, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials, with the best yet to come. Dosimetry will play a pivotal role in this course, underlying its role in clinical practice. Finally, The Alphamet project will be presented, allowing you to get updated with the latest insights from Theranostics.

RPH

Targeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment, harnessing the potent, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT, highlighting its exceptional potency, unique ability to overcome radio-resistance, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides, the biological advantages of short-range high-energy emissions, and the complex challenges involved in the development, production, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology.

Oncology

In this part of the course, participants will explore the main advantages of alpha-emitting radionuclides in oncology, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials, providing valuable knowledge on the future direction of this rapidly evolving field.

Dosimetry

Participants will begin by exploring the basic concepts of dosimetry with alpha emitters, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition, the course presents the Alphamet project, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice.

• To gain an overview of the main advantages of Alpha-radionuclides
• To learn about the challenges of alpha emitters, complex production; transport issues, waste management and handling
• To get insights on radiobiology: radiotoxicity & effectiveness
• To have a comprehensive review of research candidates
• To provide an overview of the main advantages when using Alpha-Therapy in clinical practice
• To learn about the clinical challenges when using Alpha-Therapy
• To get insights into current and future trials focusing on Alpha-Therapy
• To learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters
• To learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters
• To learn on the Alphamet project, which addresses the unique and unmet metrological challenges of targeted alpha therapies, contributing to their safe and optimised implementation into routine clinical practice

• Nuclear medicine physicians, radiologists, medical oncologists, urologists, radiation oncologists, medical physicists, biologists, researchers
• Radiochemists, radiopharmacists, physicists, medical physicists, biologists